ストックスクリーナーアプリを入手
4.36
7.39%
0.30
アフターアワーズ：
29.72
25.36
+581.65%
前日終値:
$4.06
開ける：
$4.12
24時間の取引高:
611.14K
Relative Volume:
0.59
時価総額：
$319.73M
収益：
-
当期純損益:
$-98.79M
株価収益率:
-1.3333
EPS:
-3.27
ネットキャッシュフロー:
$-51.66M
1週間 パフォーマンス:
+4.56%
1か月 パフォーマンス:
+10.38%
6か月 パフォーマンス:
+522.68%
1年 パフォーマンス:
+1,088%
1日の値動き範囲:
$4.01
$4.45
1週間の範囲:
$3.995
$4.72
52週間の値動き範囲:
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
名前
Relmada Therapeutics Inc
セクター
電話
646 876 3459
住所
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.49 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.17 | 303.77M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
5.04 | 221.34M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.67 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.76 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-05 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-06-05 | ダウングレード | Goldman | Neutral → Sell |
| 2022-10-14 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-10-14 | ダウングレード | Truist | Buy → Hold |
| 2022-10-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 開始されました | Mizuho | Buy |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-10-28 | ダウングレード | Goldman | Buy → Neutral |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-04 | 開始されました | SunTrust | Buy |
| 2020-04-21 | 開始されました | Goldman | Buy |
| 2020-01-27 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
すべてを表示
Relmada Therapeutics Inc (RLMD) 最新ニュース
Relmada Therapeutics Amends Executive Employment Agreements - TipRanks
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com
What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in
Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success - MSN
Relmada’s bladder cancer therapy shows 92% complete response rate By Investing.com - Investing.com Nigeria
Relmada’s bladder cancer therapy shows 92% complete response rate - Investing.com India
Relmada Therapeutics Advances NDV-01 for Non-Muscle Invasive Bladder Cancer with Positive Phase 2 Follow-Up Data - Quiver Quantitative
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewswire
A History of Outperforming Analyst Forecasts and Beating the Odds: Relmada Therapeutics Inc (RLMD) - setenews.com
Why Relmada Therapeutics Inc. (4E2) stock stays resilientRecession Risk & Trade Opportunity Analysis - Newser
Relmada Therapeutics (RLMD) Stock Analysis Report | Financials & Insights - Benzinga
What risks investors should watch in Relmada Therapeutics Inc. stockTrade Ideas & Fast Moving Trade Plans - Newser
How supply chain issues affect Relmada Therapeutics Inc. stockQuarterly Earnings Report & Long-Term Growth Plans - moha.gov.vn
Relmada Therapeutics Inc. (US75955J4022.SG) Balance Sheet - Yahoo! Finance Canada
Relmada Therapeutics Announces $100 Million Underwritten Offering - globallegalchronicle.com
Relmada Therapeutics Inc 4E2 Stock Analysis and ForecastVolume Analysis Techniques & Rapid Portfolio Trading - earlytimes.in
Pullback Watch: Is Relmada Therapeutics Inc. stock supported by innovation pipelineWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn
Is Relmada Therapeutics Inc. stock supported by strong cash flows - BỘ NỘI VỤ
Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - Markets Financial Content
Views of Wall Street’s Leading Experts on Relmada Therapeutics Inc - Setenews
Relmada Therapeutics Inc. (RLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Relmada cut to neutral by Mizuho on Phase 3 study failure - MSN
Relmada Therapeutics, Inc. (RLMD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
How risky is Relmada Therapeutics Inc. stock now2025 Key Lessons & Growth Focused Entry Reports - newser.com
How Relmada Therapeutics Inc. (4E2) stock trades in high volatilityEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
This Stock Is Up 704% in 2025 But Has No Products to Its Name - inkl
Will Relmada Therapeutics Inc. stock sustain high P E ratiosCEO Change & Consistent Growth Equity Picks - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Mizuho upgrades Relmada Therapeutics stock to Outperform on NDV-01 potential - Investing.com Nigeria
Smart tools for monitoring Relmada Therapeutics Inc.’s price actionWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - newser.com
Mizuho Upgrades Relmada Therapeutics (RLMD) - Nasdaq
Will Relmada Therapeutics Inc. (4E2) stock outperform small cap peers - newser.com
What valuation ratios show for Relmada Therapeutics Inc. (4E2) stock - newser.com
Mizuho Upgrades RLMD to 'Outperform', Raises Price Target | RLMD Stock News - GuruFocus
Relmada Therapeutics (RLMD) Receives Upgrade with Significant Up - GuruFocus
Relmada Therapeutics upgraded by Mizuho with a new price target - Quantisnow
Relmada Therapeutics Inc (RLMD) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
1.05%
大文字化:
|
ボリューム (24 時間):